文献速递神经创伤

造血生长因子在创伤性脑损伤亚急性期的脑修复作用

Brain repair by hematopoietic growth factors in the subacute phase of traumatic brain injury.
PubMed 文献 · J Neurosurg · 2018-01-26

该研究在小鼠右侧大脑皮质创伤性脑损伤(TBI)模型中,于伤后2周开始每日皮下注射干细胞因子(SCF,200 μg/kg)与粒细胞集落刺激因子(G-CSF,50 μg/kg)共7天。结果显示联合治疗恢复了TBI损害的空间学习与记忆、改善了焦虑与冒险行为、减少了对侧半球神经变性并提高额叶皮质树突密度,但Rota-Rod与新型物体识别测试无显著差异。

要点

  • SCF 200 μg/kg与G-CSF 50 μg/kg联合皮下注射7天,于TBI后2周开始。
  • 治疗恢复了水迷宫所示的空间学习记忆损害,并改善高架十字迷宫所示的焦虑与冒险行为。
  • Rota-Rod与新型物体识别测试中治疗组与未治疗TBI小鼠无显著差异。

核心结论

  • SCF + G-CSF治疗在TBI亚急性期恢复了TBI损害的空间学习与记忆,预防了创伤后焦虑与冒险行为,抑制了TBI诱导的神经变性,并增强了神经网络重塑。
  • 作者认为这些发现提示造血生长因子在TBI亚急性期脑修复方面具有治疗潜力。

研究设计与样本

  • 研究为小鼠实验:年轻成年雄性C57BL小鼠,在右侧大脑皮质制作TBI模型。
  • TBI诱导后小鼠随机分为2组:赋形剂对照组与SCF + G-CSF治疗组;未行TBI的小鼠作为假手术对照。
  • 治疗于TBI诱导后2周开始,SCF(200 μg/kg)与G-CSF(50 μg/kg)或等体积赋形剂溶液每日皮下注射,共7天。
  • 神经行为学测试(水迷宫、新型物体识别、高架十字迷宫、Rota-Rod)在治疗后2-9周进行;组织化学与免疫组化在治疗后11周检测两侧半球神经变性与树突密度。

主要发现

  • 水迷宫测试显示,TBI损害的空间学习与记忆被SCF + G-CSF治疗恢复。
  • 高架十字迷宫测试显示,SCF + G-CSF治疗恢复了TBI所致的焦虑与冒险行为。
  • Rota-Rod测试与新型物体识别测试中,治疗与未治疗TBI小鼠之间无显著差异。
  • 组织切片中,TBI-赋形剂对照组小鼠两侧半球广泛变性的神经元显著增多。
  • TBI诱导的神经变性增多在对侧半球被SCF + G-CSF治疗显著减少,使其与假手术对照无差异。

关键数值与推荐

  • SCF剂量200 μg/kg、G-CSF剂量50 μg/kg,每日皮下注射,共7天,于TBI诱导后2周开始。
  • 神经行为学评估时间窗为治疗后2-9周;组织学检测于治疗后11周进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVETraumatic brain injury (TBI) is a major cause of long-term disability and death in young adults. The lack of pharmaceutical therapy for post-acute TBI recovery remains a crucial medical challenge. Stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF), which are 2 key hematopoietic growth factors, have shown neuroprotective and neurorestorative effects in experimental stroke. The objective of this study was to determine the therapeutic efficacy of combined treatment (SCF + G-CSF) in subacute TBI.METHODSYoung-adult male C57BL mice were subject to TBI in the cortex of the right hemisphere. After TBI induction, mice were randomly divided into 2 groups: a vehicle control group and an SCF + G-CSF treatment group. Mice without TBI served as sham operative controls. Treatment was initiated 2 weeks after TBI induction. SCF (200 μg/kg) and G-CSF (50 μg/kg) or an equal volume of vehicle solution was subcutaneously injected daily for 7 days. A battery of neurobehavioral tests for evaluation of memory and cognitive function (water maze and novel object recognition tests), anxiety (elevated plus maze test), and motor function (Rota-Rod test) was performed during the period of 2-9 weeks after treatment. Neurodegeneration and dendritic density in both hemispheres were determined through histochemistry and immunohistochemistry at 11 weeks posttreatment.RESULTSWater maze testing showed that TBI-impaired spatial learning and memory was restored by SCF + G-CSF treatment. The findings from the elevated plus maze tests revealed that SCF + G-CSF treatment recovered TBI-caused anxiety and risk-taking behavior. There were no significant differences between the treated and nontreated TBI mice in both the Rota-Rod test and novel object recognition test. In the brain sections, the authors observed that widespread degenerating neurons were significantly increased in both hemispheres in the TBI-vehicle control mice. TBI-induced increases in neurodegeneration were significantly reduced by SCF + G-CSF treatment in the contralateral hemisphere, making it no different from that of the sham controls. Dendritic density in the frontal cortex of the contralateral hemisphere was significantly reduced in the TBI-vehicle control mice, whereas SCF + G-CSF-treated TBI mice showed significant increases of the dendritic density in the same brain region. SCF + G-CSF-treated TBI mice also showed a trend toward increasing dendritic density in the contralateral hippocampus.CONCLUSIONSSCF + G-CSF treatment in the subacute phase of TBI restored TBI-impaired spatial learning and memory, prevented posttraumatic anxiety and risk-taking behavior, inhibited TBI-induced neurodegeneration, and enhanced neural network remodeling. These findings suggest the therapeutic potential of hematopoietic growth factors for brain repair in the subacute phase of TBI.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Toshkezi G, Kyle M, Longo SL, et al. Brain repair by hematopoietic growth factors in the subacute phase of traumatic brain injury. J Neurosurg. 2018. PMID: 29372883. doi:10.3171/2017.7.JNS17878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。